Qiagen NV (QGEN) Stock Analysis

Qiagen NV (QGEN) is a publicly traded company in the HEALTHCARE sector. It trades at $35.67, carries a market capitalization of $7.46B, a price-to-earnings ratio of 18.46. This page summarizes the public market data, fundamentals, and frequently asked questions for QGEN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NYSE

Key Metrics

• Price: $35.67
• Market Cap: $7.46B
• P/E Ratio: 18.46
• EPS: $1.96
• 52-Week High: $57.82
• 52-Week Low: $32.53

Market Sentiment

Qiagen NV currently has a Neutral sentiment score of 0.13.

About Qiagen NV

Qiagen NV is a leading provider of sample-to-knowledge solutions that transform biological materials into actionable molecular insights, serving a diverse range of customers in the life sciences, clinical diagnostics, and pharmaceutical sectors. Headquartered in Venlo, the Netherlands, the company leverages advanced technologies to facilitate genomic and proteomic analysis, enabling researchers and clinicians to make informed decisions based on comprehensive molecular data. With a strong focu...

GNG Research Analysis

GNG Research scores Qiagen NV (QGEN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for QGEN.

Frequently Asked Questions

Does QGEN pay dividends?

Qiagen NV (QGEN) does not currently pay a regular dividend.

What is QGEN's P/E ratio?

Qiagen NV has a price-to-earnings (P/E) ratio of 18.46.

What is QGEN's market cap?

Qiagen NV (QGEN) has a market capitalization of $7.46B with a current stock price of $35.67.